The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Thomas Schultz Bowers - Danske Bank A/S, Research Division - Analyst
: Yes. And congratulations on the data. So a number of questions from my side here. So first of all, just wondering whether you can share how many
of the patients had at least one day reduction of PN? And if not, is it fair to assume that you are sort of close to where you normally would expect
this to be when you have a reduction number of 66%, then I think Gattex was above 50% on this. So -- any color here would be appreciated.
And then on those 9 patients that completely weaned off of PN, I believe Gattex demonstrated 2 patients. So seems like you have something that
you could argue for as a small advantage. But I'm just wondering, is if those patients when you measure this, is this at 24 weeks? Or well what I'm
trying to ask you is if this includes patients who sort of went off PN and then back on after maybe a few weeks or a couple of months? So is there
anything here that shows that this is actually a sustainable result of the GLP-2 therapy and also, of course, expected to be maintained. I'm not sure
if you have any color on the extension for these patients?
And then my last question, just on the once weekly. Normally, you would assume that the receptor does not require full exposure, at least in theory.
So is there any you would say, theoretical thoughts on why this actually fails to demonstrate a meaningful benefit also, of course, when you exclude
that single patient outlier?
Question: Thomas Schultz Bowers - Danske Bank A/S, Research Division - Analyst
: Great. And then maybe just one last small question. Your previous argued for 50 hours half-life and now on this slide to see you're up to 88 hours.
Is that some new information that you sort of discovered here? And is that comparable to what we normally see with once daily Gattex? And then,
of course, (inaudible) tied up at 72 weeks, sorry, hours?
Question: Thomas Schultz Bowers - Danske Bank A/S, Research Division - Analyst
: So are you arguing for maybe if you actually have a once-week profile, but maybe you should go up to a higher dose than 10x?
|
